COVID-19 outcomes in patients taking cardioprotective medications.
<h4>Introduction</h4>The coronavirus disease 2019 (COVID-19) caused a worldwide pandemic and has led to over five million deaths. Many cardiovascular risk factors (e.g. obesity or diabetes) are associated with an increased risk of adverse outcomes in COVID-19. On the other hand, it has b...
Main Authors: | Fritha J Morrison, Maxwell Su, Alexander Turchin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0275787 |
Similar Items
-
COVID-19 outcomes in patients taking cardioprotective medications
by: Fritha J. Morrison, et al.
Published: (2022-01-01) -
The association of cardioprotective medications with pneumonia-related outcomes.
by: Albert Wu, et al.
Published: (2014-01-01) -
PRESCRIBING PRACTICES OF CARDIOPROTECTIVE ANTI-DIABETIC MEDICATIONS IN MARGINALIZED PATIENTS
by: Raheel Khan, DO, et al.
Published: (2023-09-01) -
EXIST: EXamining rIsk of excesS adiposiTy—Machine learning to predict obesity‐related complications
by: Alexander Turchin, et al.
Published: (2024-02-01) -
Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
by: Xu Q, et al.
Published: (2021-09-01)